Biocon share news, announcements and annual reports
NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap
Biocon Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2004
Last close ₹351.80down ₹0.10 (0.03%)BSE ₹352.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹351.90.
30 Oct: open ₹352.70, high ₹355.50, low ₹348.70
52-week range of traded prices to 30 Oct 2026
₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹57,333 Cr173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 115.75
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 64.09
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.14%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,63,63747.1% delivered
Biocon share news and announcements
1,771 announcements, routine notices left out, newest first. Page 31 of 36.
Feb 2014
Jan 2014
2 Jan · Board meeting
Inter alia to approve and take on record the unaudited financial results of the Company for the quarter ended December 31, 2013.
Dec 2013
Nov 2013
Oct 2013
4 Oct · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter and half year ended September 30, 2013.
Sep 2013
Aug 2013
Jul 2013
30 Jul · Dividend
Dividend of Rs.7.50 per equity share declared by the members of the Company at the Annual General Meeting held on July 26, 2013 will be paid out on July 31, 2013.26 Jul · Updates
26 Jul · Board meeting
Board of Directors of the Company have noted the proposal for merger of its subsidiary Clinigene International Limited with Syngene International Limited, at its meeting held on July 25, 2013.3 Jul · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended June 30, 2013.
Jun 2013
19 Jun · Meeting
Company has fixed Book Closure from July 13, 2013 to July 26, 2013 for the purpose of Annual General Meeting & Declaration of Dividend. The Annual General Meeting to be held on July 26, 2013.
Apr 2013
26 Apr · Results
Consolidated Results for the year ended on 31-MAR-2013 as follows: Net Sales of Rs. 242760 lacs for year ending on 31-MAR-2013 against Rs. 204903 lacs for the year ending on 31-MAR-2012. Net Profit / (Loss) of Rs. 50882 lacs for the year ending on 31-MAR-2013 against Rs. 33843 lacs for the year ending on 31-MAR-2012.26 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2013 as follows: Net Sales of Rs. 63012 lacs for the quarter ending on 31-MAR-2013 . Net Profit / (Loss) of Rs. 24861 lacs for the quarter ending on 31-MAR-2013.26 Apr · Results
Standalone Results for the year ended on 31-MAR-2013 as follows: Net Sales of Rs. 183748 lacs for year ending on 31-MAR-2013 against Rs. 150480 lacs for the year ending on 31-MAR-2012. Net Profit / (Loss) of Rs. 27570 lacs for the year ending on 31-MAR-2013 against Rs. 25550 lacs for the year ending on 31-MAR-2012.26 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2013 as follows: Net Sales of Rs. 45757 lacs for the quarter ending on 31-MAR-2013 . Net Profit / (Loss) of Rs. 3829 lacs for the quarter ending on 31-MAR-2013.26 Apr · Management
Board of Directors of the Company at its meeting held on April 25, 2013 has appointed Mr Daniel M Bradbury as an Additional Director of the Company . He will hold office up to the date of ensuing Annual General Meeting, wherein his appointment as a Director will be placed before shareholders for approval.26 Apr · Dividend
He Board of Directors of the Company at its meeting held on April 25, 2013 has recommended a final dividend of Rs. 5/- per share (i.e. 100%) and a special dividend of Rs. 2.50/- per share (i.e.50%) for the financial year 2012-13.The declaration of dividend is subject to shareholders' approval at the ensuing Annual General Meeting of the Company. Subsequent to Shareholders' approval the dividend will be paid within a period of 30 days from the date of such approval.9 Apr · Board meeting
Inter alia, to: (a) Approve and take on record the audited Financial results for the year ended on March 31, 2013.and (b) Consider recommendation of payment of dividend, if any, for the year 2012-2013.
Mar 2013
Feb 2013
27 Feb · Disclosure
14,500 (Fourteen Thousand Five Hundred Only) equity shares of the Company were transferred to employees from the ESOP Trust pursuant to exercise of stock options by them. There is no change in the listed and paid-up share capital of the Company pursuant to the exercise of said stock options.
Jan 2013
8 Jan · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on December 31, 2012.
Nov 2012